Amgen Inc.

Elephas Biosciences Corporation

Medarex Inc.

Jonathan Daniel Oliner

Hosung Min

Thomas Charles Boone

Sean Caenepeel

John Rafter

Tomasz Zal

Laura Catherine Funk Hrycyniak

Neil Anthony

Paul G Hughes

Kevin Graham

Anne Y Saiki

Jude Robert Canon

Eunkyung Lee

Richard J Rickles

Rakesh Kumar

Paul Hughes

Richard Kendall

Provided are ex vivo systems and methods of predicting the response of a drug or other agent on a tissue. In some embodiments, the systems and methods comprise cutting a tissue into tissue fragments, adding a drug or other agent to the tissue fragments based on an estimated tumor content, and performing an ex vivo measurement on the tissue fragments.

Ex vivo systems and methods for determining the effect of a drug or other agent on a tissue

The present invention provides combination therapy that includes an MDM2 inhibitor and one or more additional pharmaceutically active agents, particularly for the treatment of cancers. The invention also relates to pharmaceutical compositions that contain an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers.

Combination therapy including an MDM2 inhibitor and one or more additional pharmaceutically active agents for the treatment of cancers

Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin 1 and/or angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.

Antibodies directed to angiopoietin-1 and angiopoietin-2 and uses thereof

Disclosed are peptides that bind to Ang-2. Also disclosed are peptibodies comprising the peptides, methods of making such peptides and peptibodies, and methods of treatment using such peptides and peptibodies.

Specific binding agents of human angiopoietin-2

Methods of treatment using specific binding agents of human angiopoietin-2

Disclosed are specific binding agents, such as fully human antibodies, that bind to angiopoietin-2. Also disclosed are heavy chain fragments, light chain fragments, and CDRs of the antibodies, as well as methods of making and using the antibodies.

Angiopoietin-2 specific binding agents

Growing community of inventors

Newbury Park, CA, United States of America

Jonathan Daniel Oliner